CVT Ranexa complete response
This article was originally published in Pharmaceutical Approvals Monthly
CV Therapeutics submits its "complete response" to an October 2003 "approvable" letter for its angina treatment Ranexa (ranolazine) July 27. The amendment seeks a narrowed indication based on the FDA-requested ERICA (Evaluation of Ranolazine in Chronic Angina) study of patients refractory to Pfizer's Norvasc (amlodipine), which compared the partial fatty acid oxidation inhibitor plus the maximum labeled dose (10 mg) of Norvasc to Norvasc alone. CVT has said that the 0.4 attack/week reduction seen in ERICA was sufficient for an indication for a restricted population, despite being less than half the projected 1.0-1.2 reduction (1Pharmaceutical Approvals Monthly May 2005, p. 10). Assuming a six-month review of the amendment, Ranexa could launch in the first half of 2006...
You may also be interested in...
A mean weekly reduction of 0.4 angina attacks seen in the ERICA study with CV Therapeutics' Ranexa (ranolazine) is adequate for approval, the company said, despite being less than half the expected decrease
The UK has an “excellent but small diagnostics industry,” so it needs further testing support from related life science industries to tackle the COVID-19 crisis. One of the outcomes of this could be the creation of new big diagnostics industry players.
Medicinal products authorities will consider a medtech notified body opinion on the device element of a drug/device combination product. A new position paper explains how roles and responsibilities are shared between medtech and medicinal product experts.